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Inﬂammatory bowel disease (IBD) is a group of chronic inﬂammatory disorders that aﬀect individuals throughout life. Although
the etiology and pathogenesis of IBD are largely unknown, studies with animal models of colitis indicate that dysregulation of
host/microbial interactions are requisite for the development of IBD. Patients with long-standing IBD have an increased risk for
developing colitis-associated cancer (CAC), especially 10 years after the initial diagnosis of colitis, although the absolute number
of CAC cases is relatively small. The cancer risk seems to be not directly related to disease activity, but is related to disease
duration/extent, complication of primary sclerosing cholangitis, and family history of colon cancer. In particular, high levels and
continuous production of inﬂammatory mediators, including cytokines and chemokines, by colonic epithelial cells (CECs) and
immune cells in lamina propria may be strongly associated with the pathogenesis of CAC. In this article, we have summarized
animal models of CAC and have reviewed the cellular and molecular mechanisms underlining the development of carcinogenic
changes in CECs secondary to the chronic inﬂammatory conditions in the intestine. It may provide us some clues in developing a
new class of therapeutic agents for the treatment of IBD and CAC in the near future.
1.Introduction
Crohn and Rosenberg ﬁrst reported the UC case associated
with colorectal cancer development in 1925 [1], and the
association between colitis and colorectal cancer is widely
accepted currently. It is assumed that chronic inﬂammation
is a direct cause of CAC; however, it is not until 10 years after
disease onset when a risk of colon cancer development in
IBD patients becomes signiﬁcant. The risk is approximately
ﬁve times higher than in the general population. Eaden
et al. reported that the cumulative incidence of colorectal
cancer in UC patients was 2% at 10-year, 8% at 20-year,
and 18% at 30-year with followup study [2]. The important
risk factors include family history of colon cancer, disease
duration/extent, and concurrent primary biliary cholangitis
[3, 4]. The cancer risk seems to be closely associated with
the extent of colonic involvement and length of time since
disease onset [5]. To detect microscopic foci of dysplasia or
early stage ofcancer, IBDpatientsneed toundergoanannual
colonoscopy with multiple biopsies. A minimum of 33
samplesandatotalof50ormorebiopsieswillbenecessary to
achieveahighconﬁdence(90%–95%)ofdetectingcancerous
region(s) [6, 7]. A tremendous amount of eﬀort is currently
being directed toward improving colonoscopic technology
and developing genetic and serological markers [8]. At this
time,however,onlya limitedamount ofdataare availablefor
understanding the exact mechanisms of how chronic colitis
is connected to the development of colorectal tumors.
The small and large intestines both contain an abun-
dance of luminal antigens, including food products and
enteric microorganisms. Intestinal epithelial cells provide
an important barrier between the potentially hazardous
luminal contents and immune cells in the situated lamina
propria [9, 10]. The function of colonic epithelial cells2 Journal of Biomedicine and Biotechnology
(CECs) is tightly regulated by many soluble factors derived
from enteric bacteria and epithelial cells themselves [11,
12]. CECs actively participate in the detoxiﬁcation and
biotransformation of xenobiotics [13, 14], and the failure of
these important functions leads to epithelial cell injury and
intestinal inﬂammation [15]. The development or perpetua-
tion of intestinal inﬂammation is also closely associated with
the induction of several molecules on CECs including Toll-
like receptors (TLRs) and tumor necrosis factor receptors
(TNFRs)[14, 16, 17]. So far, many animal models of chronic
colitis and colitis-associated cancer (CAC) provide evidence
that a variety of inﬂammatory mediators play pivotal and
speciﬁc roles in the initiation and development of colitis and
CAC [18]. In particular, TNF and TNFR ligation activated
NF-κB and its downstream cell survival pathways seem to
highlycontributetothedevelopmentofcolorectalcarcinoma
[19]. IL-6 is another important cytokine which controls the
transition between innate and acquired immune responses
[20], and increased levels of IL-6 have been detected both
in human colon cancer patients and murine models of
CAC[21]. In addition, mRNAexpression ofCC-chemokines
including CCL-2 (MCP-1) is highly upregulated in the
colonic mucosa of IBD patients as well as in the AOM
pretreated DSS-colitis model [22–24]. Our group recently
identiﬁed that one of the mammalian chitinases, chitinase
3-like-1 (CHI3L1/YKL-40), is signiﬁcantly upregulated in
message and protein levels in the colonic mucosa of IBD
patients with active inﬂammation as well as murine models
of colitis, [14] and this molecule seems to play an active role
in the neoplastic transformation of epithelial cells [25, 26].
Therefore, inﬂammatory cell inﬁltration and their secreting
solublemediatorsare keyplayersinregulating pre-neoplastic
growth of CECs in colitis-associated tumorigenesis.
In this paper, we have concisely summarized the pre-
viously reported animal models of CAC and will discuss
possible roles of inﬂammatory mediators and their receptors
in the chronically inﬂamed colonic mucosa during the
development of chronic inﬂammation and CAC.
2.Overview:DifferencesbetweenSporadic
ColonCancerand CAC
Sporadic colorectal cancer, the major form of colon cancer,
occurs in people with little or no family history of the
disease. This type of cancer often arises from successive
accumulationofmutationsingenescontrollingepithelialcell
growth and diﬀerentiation. Genomic instability is important
to the development of colon cancer; however, the process
that causes this genomic instability is not completely under-
stood. Two major types of genomic instability, chromosomal
instability and microsatellite instability (MSI), contribute
to colonic carcinogenic processes. MSI-positive colorectal
carcinomas can be further divided into those with high
(MSI-H) or low (MSH-L) levels of MSI depending on
how many markers are unstable on a consensus panel
[27]. High-level MSI accounts for approximately 15% of
sporadic colorectal cancers, while the remaining 85% are
attributedtochromosomal instability[28].MSI-Hcolorectal
cancers neither exhibit gross cytogenetic abnormalities nor
display allelic losses at tumor suppressor loci frequently,
and they are not generally aneuploid. Colorectal carcino-
mas originating by the suppressor and mutator pathways
diﬀer in pathological features [29]. These tumors are likely
to be present in the proximal colon, demonstrate poor
diﬀerentiation, have mucinous or medullary features, and
display more prominent lymphocytic inﬁltration compared
to microsatellite stable tumors or MSI-L tumors.
As described above, colorectal cancer can be caused by
chromosomal instability. This is characterized by widespread
imbalances in chromosome number (aneuploidy), caused by
defects in chromosomal segregation. Mutations in speciﬁc
tumor suppressor genes and oncogenes that activate path-
ways critical for cancer development, which are important
for the initiation and progression through the cell cycle, are
seen in colorectal cancer [30, 31]. The mitotic checkpoint
(the spindle assembly checkpoint) is a major cell-cycle
control mechanism that ensures proper chromosome seg-
regation by delaying anaphase progression until all pairs of
chromosomes are properly aligned on the metaphase plate.
Defects in checkpoint signaling lead to chromosome misseg-
regationandsubsequentaneuploidywithabnormalnumbers
of chromosomes being distributed to daughter cells [32].
The products of two genes, mitotic arrest-deﬁcient (MAD)
and budding uninhibited by benzimidazoles (BUB), operate
as checkpoint sensors and signal transducers that control
sister chromatid separation. The activation of these leads
to inhibition of the anaphase-promoting complex (APC/C),
a large ubiquitin-protein ligase, and cell-cycle arrest.
MAD3/BUBR1, MAD2, and BUB3 associate with APC/C-
activating molecule CDC20 to form the mitotic checkpoint
complex and induce a conformational change in APC/C,
which prevents binding and ubiquitination of its substrates
[33]. The APC/C activation leads to degradation of securin
(a protein involved in control of the metaphase-anaphase
transition and anaphase onset) and activation of separases
(a class of caspase-related proteases). Separase regulates a
multiproteincomplextermedcohesin,which createsphysical
links between sister chromatids thatare maintained until late
mitosis. The errors in this system lead to unequal chromo-
somal segregation [34]. In colorectal cancer, mutations have
been found in hZw10, hZwilch/FLJ10036, and hRod/KNTC,
which are kinetochore proteins that function at the spindle
checkpoint. Another mutation is observed in Ding gene,
which regulates proper chromosome disjunction [35].
Another mechanism leading to chromosome instability
is abnormal centrosome number and function. Centro-
somes coordinate mitosis by serving as an anchor for the
reorganization of cytoplasmic microtubules into a mitotic
spindle apparatus. When extra centrosomes are present,
they lead to the formation of multiple spindle poles during
mitosis, resulting in an unequal distribution of chromo-
somes. When centrosomes cluster, an increased rate of
merotelic chromosomal attachment to spindle can cause
chromosomal missegregation and ultimately chromosomal
instability [36]. A third mechanism is a mutation in
Aurora B, a kinase regulating chromosome segregation. An
overexpression of Aurora B correlates with advanced stagesJournal of Biomedicine and Biotechnology 3
of colorectal cancer. This is the catalytic component of
the chromosomal passenger complex that regulates accurate
segregation of chromatids at mitosis, histone modiﬁcation,
and cytokinesis [37]. Finally, the elevated expression of PIK1
(aserine/threonine kinasewhich regulatesentry intomitosis,
centrosome duplication, and transition from metaphase to
anaphase,andcytokines)isalsoobservedincolorectalcancer
[38, 39]. All of these mutations lead to colorectal cancer
through chromosomal instability and aneuploidy.
Chronic inﬂammatory diseases are associated with an
increased risk of cancer, and IBD patients have a higher
risk of developing CAC approximately 8–10 years after the
initial diagnosis as compared to general population. In
addition to genomic instability that underlies the process
of tumorigenesis, continuous inﬂammation in the intestine
seems to be a key factor in CAC development since chronic
inﬂammation is associated with elevated levels of proin-
ﬂammatory cytokines, chemokines, growth factors as well
as their receptors, and reactive oxygen species. In particular,
oxidative injury, causing widespread DNA damage, leads
to the inception of cancer. Crypt ﬁssion (duplication of
crypts by branching) propagates these heterogeneous DNA
changes from one crypt to another. In fact, crypt ﬁssion is
a natural way to duplicate the heterogeneous changes that
are sometimes observed in the crypt units of UC patients.
Eventually, some of these changes may induce a growth
advantage and clonal expansion of CECs, and some of the
mutational changes in one crypt can be found in thousands
of adjacent crypts. The ﬁnal stages of tumorigenesis in the
chronic inﬂammatory setting occur when an accumulation
of select mutations allows clonal progression to overtake the
balancing forces of cell death and loss [40].
3.SpontaneouslyDevelopedAnimal
Models of CAC
A summary of CAC development in genetically engineered
animal models of colitis has been shown in Table 1.W e
have further discussed some selected models, which are
includedor not includedin Table 1,i nth i ss e cti o n .Al th o u gh
adenomatous polyposis coli (APC) multiple intestinal neo-
plasia (min) mice do not develop adenocarcinoma, these
micedevelopnumerousadenomatouspolypsthroughoutthe
smallandlargeintestine,andtherefore,wehaveincludedthis
model in the following section.
3.1. APC-Min Mice Model. APC is a multidomain protein
translated from the APC gene and composed of 2843 amino
acids,which functionstoregulatedownstream Wntsignaling
bybindingtoβ-catenin andpromotingitsdegradation.APC,
along with AXIN, GSK-3β,E B 1 ,a n do t h e rp r o t e i n s ,f o r m s
ac o m p l e xt h a tb i n d st oβ-catenin. This complex formation
preventsthenuclear translocation ofβ-catenin and causes its
phosphorylationand, subsequently,itsdegradationbya pro-
teasome.Inthisway,APCactually actsasatumorsuppressor
gene by preventing the continuous activation of β-catenin. A
mutation or loss of APC genes results in the upregulation of
transcriptional targets such as c-myc and cyclin D1 [53].
Loss or mutation of APC is an early causative event
in familial and sporadic colon cancer pathogenesis. The
most common mutations in familial adenomatous polyposis
(FAP) are deletions in codons 1309 (10% occurrence) and
1061 (5% occurrence) [54]. The mutations in these same
codonsaccountfor30%ofgermlinemutations.Themajority
of germline mutations found in FAP patients are nonsense
mutations, which cause the formation of a truncated protein
because of the insertion of an early stop codon. Most of
the mutations to APC represent truncating mutations, of
which, 46% are small deletions, 10% are small insertions,
28% are nonsense mutations, and 13% are gross alterations.
More than 60% of APC mutationsare found in the mutation
cluster region (MCR, amino acids 1284–1580), the region
that is most important for the downregulation of β-catenin
and for the pathogenesis of colorectal cancer. Many of these
mutations lead to the generation of a truncated protein,
which causes the loss of APC protein function [54, 55].
APCmin mice, homozygous for the mutation, experience
embryonic lethality. However, those that are heterozygous
for the mutation are viable and develop more than ﬁfty
adenomas in the intestinal tract. The small intestine is
most commonly the site of these tumors. These mice can
also develop a variety of lesions in other organs such as
desmoids tumors, epidermoid cysts, and mammary tumors
[56]. Most APCmin mice only survive to 120 days, at which
point they die of the excess tumor formations in their
small intestines [57]. In APCmin/+ mice, diﬀerent areas of
the gene, such as the EB1/RP1 binding area, DLG/PTP-
BL binding area, nuclear export/import signals, the CDK
consensus phosphorylation site p34-cdc2 binding, the β-
catenin binding site, β-catenin downregulation site, and
Axin/conductin binding site, are missing by truncational
mutations [55]. Because APC is an important molecule in
the formation of colorectal cancer, mouse models have been
developed to study the physiological and biological function
of this protein in polyp formation. APCmin/+ mice have
been widely utilized for studying the eﬀects of this protein
under controlled experimental conditions. APCmin/+ mice
were treated with ethyinitrosourea (ENU) to induce colitis,
and multiple intestinal neoplasia was observed carrying a
nonsense mutation [56, 58].
The APCmin mutation initiates mitotic defects in histo-
logically normal crypt cells of the murine small intestine, in
which misoriented spindles, misaligned chromosomes, and
tetraploid cells are frequently observed. In addition, changes
in crypt size, cell proliferation, and apoptosis have been
observed [55]. The cells in these APC deﬁcient crypts show
reduced crypt to villus migration and diﬀerentiation. Chro-
mosomal instability resulting in losses and/or gains of chro-
mosomal regions and microsatellite instability, which results
from mismatch repair deﬁciency, is another change observed
in APC deﬁcient mice. Microadenoma formation, visible in
these mice, could result from DNA hypomethylation.
Secretory Phospholipase 2 (sPLA2) is a key enzyme
involved in the release of arachidonic acid from membrane
lipids in the synthesis of prostaglandins. The loss of sPLA2
increases APC driven tumorigenesis. In addition, PLA2g4
(group 4 cytosolic phospholipase A2 catalyzes the hydrolysis4 Journal of Biomedicine and Biotechnology
Table 1: Summary of CAC in genetically engineered animal models of colitis.
Model Characteristics Tumor histology Tumor location Incidence of cancer References
IL-2 x β2-M DKO UC-like Carcinoma Rectum, colon 32%
adenocarcinoma Sohn et al., 2001 [41]
IL-10 KO CD-like duodenitis,
colitis Carcinoma Colon, rectum 60%
adenocarcinoma
Shattuck-Brandt et al.,
2000 [42]
RAG2 KO Induced by infecting
with H. hepaticus
Dysplasia, tubular
adenoma, carcinoma,
adenocarcinoma
Cecum, colon 100%
adenocarcinoma Erdman et al., 2003 [43]
RAG2/Tgfβ1D K O C o l i t i s Dysplasia,
adenocarcinoma Cecum, colon 100%
adenocarcinoma Erdman et al., 2003 [43]
TCRβ/p53 DKO UC-like Dysplasia,
adenocarcinoma Ileocecum, cecum 70%
adenocarcinoma Kado et al., 2001 [44]
Gpx1/Gpx2 DKO Ileocolitis
Dysplasia,
adenocarcinoma,
signet ring cell
carcinoma
Ileum, colon 28%
adenocarcinoma Chu et al., 2004 [45]
Gαi2 KO UC-like Carcinoma Colon 31%
adenocarcinoma Rudolph et al., 1995 [46]
Msh2 KO HNPCC Adenoma,
adenocarcinoma Jejunum 38.9%
adenocarcinoma Reitmair et al., 1996 [47]
Msh3 x Msh6 DKO HNPCC
Adenoma,
adenocarcinoma,
lymphoma
GI tract 81.3%
adenocarcinoma Edelmann et al., 2000 [48]
Msh6 KO HNPCC
Adenoma,
adenocarcinoma,
lymphoma
GI tract 38.5%
adenocarcinoma Edelmann et al., 2000 [48]
Mlh1 KO HNPCC Adenomas,
adenocarcinomas GI tract
72.0% tumor
incidence
9.36%
adenocarcinoma
Edelmann et al., 1999 [49]
Mlh3 KO HNPCC Adenomas,
adenocarcinomas GI tract
52% tumor
incidence
14%
adenocarcinoma
Chen et al., 2005 [50]
Mlh3 x Pms2 DKO HNPCC Adenomas,
adenocarcinomas GI tract 42% tumor
incidence Chen et al., 2005 [50]
Msh2G674A/G674A HNPCC Adenocarcinomas GI tract 19%
adenocarcinoma Lin et al., 2004 [51]
MlhG67R/G67R HNPCC
Adenocarcinoma,
adenoma, squamous
basal cell carcinoma
GI tract 61%
adenocarcinoma Avdievich et al., 2008 [52]
Abbreviations: CD, Crohn’s disease; DKO, double knockout; GI, gastrointestinal; HNPCC, hereditary nonpolyposis colorectal cancer; KO, knockout;R A G ,
recombination-activating gene: UC, ulcerative colitis.
of membrane phospholipids to release arachidonic acid)
suppresses tumor multiplicity in APCmin/+ [57]. Although
APCmin/+ mouse is a good model of colitis, there are
diﬀerences between the progression of disease in mice and
humans. In APCmin/+ mouse model, the polyp formation
occurs mainly in the small intestine, while this formation
occurs mainly in the colon in humans. In addition, there
is very little or no invasion of the submucosa by tumors
in APCmin/+ mice, and the tumors do not develop into
adenocarcinomas [59].
APCmin h a si n t e r a c t i o n sw i t ho t h e rg e n e sa sw e l l .
Previous studies have shown that one of the downstream
targets of Wnt signaling, cyclin D1, was not upregulated
immediately after APC loss and did not contribute to the
early phenotype in colon cancer. In contrast, the loss of
both proto oncogene c-myc and APC has a crucial role in
early stages of sporadic colorectal carcinoma development.
As argued by some investigators, loss of APC function is
typically an early stage event in the pathogenesis of sporadic
colorectal carcinoma, but APC mutation itself seems to be a
later stage (from high-grade dysplasia to adenocarcinoma)
of tumor progression in CAC, suggesting APC mutation
may not be the universal initiating event in colon cancer
[27]. However, loss and/or truncation of APC still highly
contributes to the cause of mitotic spindle defects that,
upon somatic inactivation of other chromosomal instabilityJournal of Biomedicine and Biotechnology 5
genes (e.g., spindle and cell-cycle checkpoint genes, DNA
repair, and telomerase maintenance), underlie aneuploidy as
observed in the majority of colorectal cancer [60].
3.2. IL-10 Knockout (KO) Mice Model. IL-10 is a key regu-
lator of the pathogenesis of IBD. Patients with mutated IL-
10 signaling systems show early and aggressive development
of systemic inﬂammation including IBD. IL-10 KO mice
also develop spontaneous colitis and CAC with aberrant
Th1cytokine production. The histopathology of chronic col-
itis in IL-10 KO mice is characterized by epithelial hyperpla-
sia, inﬂammatory inﬁltrates in the mucosa and submucosa,
andcryptabscesses[61].Theinﬂammatory inﬁltratesconsist
ofsmall tomoderatenumbersofneutrophilsandeosinophils
as well as lymphocytes, plasma cells, and macrophages,
and may involve the intestine transmurally. Six-month-old
mice showed other lesions characterized by irregular glands,
back-to-back growth of glands,s m a l ln e s t so fe p i t h e l i a l
cells in the intestinal walls, ﬁbrosis, and slight loss of
nuclear polarity consistent with adenocarcinoma [61]. No
metastasis in lymph nodes and liver were observed at this
age [62]. Although the adenocarcinomas in IL-10 KO mice
are histologically very similar to those seen in IBD patients,
the lack of involvement of K-ras, p53, APC, and MSH genes
indicatesthatIL-10KOmicearenotoptimalforinvestigating
IBD-associated carcinogenesis [63].
The development of CAC in IL-10 KO mice has been
demonstrated in C57BL/6/129-Ola mixed background mice.
These IL-10 KO mice have a 25% incidence of developing
adenocarcinoma after 3 months of age. After 6 months of
age, they have a 60% incidence of adenocarcinoma [61].
Similarly, it was found in another study that IL-10 KO
mice develop tumors, the majority of which are invasive
adenocarcinomas, between 25 and 35 weeks of age [64].
Finally, a third study showed the incidence of adenocarci-
nomas was 14% at 9 weeks of age and 65% at 10–31 weeks
of age [62]. When recombinant IL-10 was administered
to these mice, the incidence of adenocarcinoma decreased
from 67% to 28%. In addition, the background of the
mice inﬂuences the incidence of adenocarcinoma; IL-10 KO
Balb/c, IL-10 KO 129 SvEv, and IL-10 KO C57BL/6 have
incidences of 29%, 67%, and 0%, respectively, at 3 months
of age [39]. IL-10 KO mice in 129SvEv background showed
epithelial extension/invasion mainly in the ascending colon
and subsequently developed adenocarcinomas at 6 months
of age without showing any signs of metastatic disease [65].
The development of adenocarcinoma in IL-10 KO mice
seems to be associated with colonic bacterial infection [66].
IL-10 KO mice infected with Helicobacter typhlonius had a
40% incidence of invasive adenocarcinoma, and the pups
born to these mothers, as well as mice infected as pups, had
an 18% incidence of colon cancer. In contrast, mice infected
with Helicobacter rodentium had a 0% incidence of invasive
adenocarcinoma. Interestingly, however, pups born to these
mothers and mice infected as pups had an incidence of 12%.
Finally, mice infected with both types of bacteria had a 57%
incidenceofinvasive adenocarcinoma.Itis hypothesized that
the bacteriainfect the mice byburrowing throughthe mucus
to grow adjacent to the intestinal epithelial surface, where
they degrade the barrier properties. This causes injurious
leakage of bacterial antigens into the mucosa, which causes
an immune response that in turn leads to the development
of IBD and subsequently adenocarcinoma in the host [66].
AOM and DSS treatment promotes inﬂammation-
mediated colonic tumor growth in IL-10 KO mice [67]. Fur-
thermore, Helicobacter hepaticus infection accelerates AOM-
induced tumorigenesis compared to AOM treatment alone
in IL-10 KO mice [68].
IL-10KOmice crossedtohuman MUC1-transgenic mice
developed much more severe colitis with a signiﬁcantly
higher incidence of colon cancer as compared to IL-10 KO
mice [64]. MUC-1 has been reported to be overexpressed
in IBD and adenocarcinoma, while its expression levels in
normal and healthy CECs are low. Interestingly, vaccination
against MUC1 delays IBD onset and also prevents CAC
development in these mice, suggesting that the induction
of MUC1-speciﬁc adaptive immune responses, such as anti-
MUC1 IgG and anti-MUC1 CTL, regulate local and systemic
immunity by eliminating abnormal MUC1-positive cells in
the IBD colon [64].
3.3. Gαi2 KO Mice Model. G proteins (guanine nucleotide-
binding proteins) are signal transducing proteins that couple
a large family of receptors to eﬀectors such as adenylyl
cyclase, phospholipase C, and ion channels [69]. Receptor-
activated G proteins are subsequently bound to the inner
surface of the cell plasma membrane, which consists of the
Gα and Gβγ subunits. There are four classes of Gα subunit,
namely, GαS, Gαi, Gαq/11, and Gα12/13. Gαi inhibits the
production of cAMP from ATP A C-terminal splice variant
of αi2, which localizes to the Golgi apparatus and could
be involved in membrane transport [70]. The inhibition of
adenylyl cyclase, stimulation of inwardly rectifying and ATP
sensitive K+ channels, regulation of ﬁbroblast proliferation,
stimulation of MAP kinase pathway, diﬀerentiation of F9
teratocarcinoma cells into primitive endoderm, and regula-
tion of neonatal growth and development are all dependent
on this [46]. To further analyze the biological function of
G proteins in cellular signaling and cell diﬀerentiation, KO
mice for Gαi2 gene were generated by Rudolphs et al. [70].
These mice developed an IBD with clinical and histological
features strikingly similar to UC, including the development
of adenocarcinoma of the colon [46, 70]. Gαi2 KO mice
withcoloniculcerationshadfociofregenerativeproliferation
of glandular epithelium through the full thickness of the
mucosa and, in some foci, both the inﬂammation and glan-
dular epithelium penetrated into the submucosa. Approxi-
mately 30% of mice showed highly atypical glands charac-
terized by back-to-back growth without intervening stroma,
loss of nuclear polarity, and marked crowding indicative of
colon cancer; however, polypoid growthswere not evidentin
these mice [46]. Migration of circulating leukocytes into the
intestinal mucosa was partially dependent on α4 integrins,
and short-term administration of antiα4 integrin antibodies
was eﬀective to attenuate intestinal inﬂammation in some
animal models of colitis and human clinical trials [71–74].6 Journal of Biomedicine and Biotechnology
However, Hornquist’s group showed that long-term (three
times/week for 9 weeks) blockade of α4 integrin signiﬁcantly
i n c r e a s e dt h es e v e r i t yo fc o l i t i sa sw e l la sc a n c e ri n c i d e n c e
and also showed decreased levelsof total IgA and IgG level in
the sera of Gαi2 KO mice [75]. Therefore, caution needs to
be made upon applying a long-term treatment with anti-α4
integrin antibody in clinical trials.
3.4. Chronic Colitis and CAC in Cotton Top-Tamarin (CTT).
CTT is one of the best primate models for studying colitis
and CAC although it is not currently used because of the risk
of extinction.
CTT was previously an important primate model for
the study of colitis and CAC because, like humans, it
spontaneouslydevelopscolitiswhich oftenleadstocolorectal
cancer. The CTT’s natural habitat is a rain forest located
in northwestern Colombia, South America [76]. CTT were
initially imported to the United States in the 1960s and
were used for infectious studies with Herpes samirii, Herpes
ateles, and the Epstein-Barr virus. However, all research
studies were withdrawn when the CTT were placed on the
endangered species list in 1977. During the reconstruction
eﬀort of the CTT breeding colonies, it was found that
chronic ulcerative colitis and colonic adenocarcinoma were
to be major health problems for this species [77, 78].
Approximately 80% of the captive CTT developed active
colitis that would eventually lead to low-to-high grade
dysplasia and colonic adenocarcinoma [76]. Another group
also identiﬁed that 65.4% of captive CTT showed severe
colitis but none in wild CTT, and 19.5% of captive CTT
showed moderate colitis but only 13% in wild CTT [79]. In
CTT,species-related susceptibilityandinfection (e.g.,corona
viruses, Campylobacter, Helicobacter, and enteropathogenic
Escherichia coli)seemtobeoneofthecausesofchroniccolitis
[77, 80]. Other extrinsic/intrinsic factors include disruption
of the immune system, family history of CTT, short-chain
fatty acids (SCFAs), carcinoembryonic antigens (CEAs), and
environmental stress. A unique member of Helicobacter is
found in the intestines and feces of CTT with chronic
colitis. This particular strain lacks urease activity and fails to
hydrolyze alkaline phosphatase. The pathogenicity remains
unknown, but since the Helicobacter family is considered
to be responsible for inﬂammation and hyperplasia of
epithelial cells and predisposes an individual to neoplasia, it
is conceivable that this novel Helicobacter may play a role in
contributing to UC and CAC of CTT [79].
Watkins et al. utilized a humanized anti-TNFα mon-
oclonal antibody (CDP571) in treatment for the spon-
taneously developed colitis in CTT, and showed rapid
improvementin clinicalparameters [81]. This result strongly
suggests that TNFα overproduction is likely a critical
pathogenic factor in spontaneously developedchronic colitis
in CTT. Several clinical studies have established that a
chimeric (75% mouse/25% human) anti-monoclonal anti-
body (Inﬂiximab) is beneﬁcial in the treatment for IBD
[82, 83]. In particular, Inﬂiximab is an eﬀective maintenance
therapyforﬁstulizing CD[84]andisuseful forthe treatment
of mucosal ulceration associated with CD [83].
It is also noted that disrupting inﬂammatory media-
tors (neutrophils, lymphocytes, monocytes, eosinophils, and
mast cells)are involvedin thedevelopmentofchronic colitis.
Two research groups elegantly demonstrated that admin-
istration of monoclonal antibodies directed against either
E-selectin or integrin α-4 (one of the subunits of VLA4)
attenuated colitis in CTT [73, 74]. Since the followup animal
studies by other groups also conﬁrmed an important role
of α-4 integrins in the migration of circulating leukocytes
into the intestinal mucosa, a clinical trial using Natalizumab
(a humanized anti-α-4 monoclonal antibody) for CD was
initiated, and showed a statistically signiﬁcant eﬀect in the
initial trial [71, 85]. However, the following clinical trial
could not conﬁrm the beneﬁt [86]. In addition, during
the treatment with Natalizumab, some patients developed
progressive multifocal leukoencephalopathy secondary to
reactivation of the JC virus, a human polyomavirus that is
typically acquired during childhood and remains latent in
the kidneysand possibly othersites in up to 80% of the adult
population [87]. Furthermore, blockade of α4i n t e g r i ne x a c -
erbated the chronic colitis and increased cancer incidence in
aG αi2 KO mice model [75]. Based on these results, eﬃcacy
of Natalizumab for CD is highly questionable, and it carries
a potential risk of severe complications [88].
4.ChemicallyInducedColitis-Associated
CancerModel
4.1. Chronis DSS-Induced CAC Model. To reproduce the
clinical course of UC experienced in humans, which is
characterized by the spontaneous onset of active inﬂam-
mation with separated periods of disease inactivity, DSS is
administered for 3–7 days in mice to induce inﬂammation
of the colon, followed by regular water administration for
1-2 weeks to permit healing of the colonic mucosa. Several
“cycles” of DSS administration have also been used in order
to augment carcinogenesis as observed in chronic ulcerative
colitis patients. Squamous metaplasias of the rectal mucosa,
squamous papilloma, adenoma, and adenocarcinoma have
been observed in the treated mice. During the develop-
ment of DSS-induced colorectal tumor, several genes, and
molecules play pivotal roles in the pathogenesis. We have
summarized some of the important factors in the following
s e c t i o na sw e l la si nT a b l e s2 and 3.
4.1.1. APC. The APCmin/+ mutation is found in 80% of
sporadic colorectal cancers and is found in 4%–27% of CAC
[109]. To test the eﬀects of this gene on CAC development,
colitis was induced in APCmin/+ mice. These APC+/min mice
(C57BL/6J strain) were treated with 2 cycles of DSS. The
ﬁrst cycle of DSS administration consisted of 4 days of
4% DSS followed by 17 days of regular water. The second
cycle consisted of 3 days of 4% DSS followed by 18 days
of regular water. In another experiment, the mice (female,
B6 background) were treated with 4 cycles of DSS with
each cycle consisting of 4 days of 4% DSS and 17 days of
regular water. Through these treatments, a two-fold (50%
to 100%) increase in tumor incidence was found [100].Journal of Biomedicine and Biotechnology 7
Table 2: Summary of CAC in chemically induced colitis models.
Models Animal species Treatment Duration Selected references
Carrageenan Rats
5%–10% degraded
carrageenan in diet,
drinking water or by
stomach tube
2, 6, 9 months or up
to 24 months
Ashi et al., 1978 [89]
Oohashiet al., 1981 [90]
Ishioka et al., 1987 [91]
Tobacman, 2001 [92]B e n a r d
et al., 2010 [93]
Dextran Sulfate
Sodium (DSS)
C57Bl/6J 0.1%–0.4% DSS 60 days Chromik et al., 2007 [94]
C57Bl/6J 0.7% DSS
15 cycles of: 1 week
DSS followed by 10
days water
Kim et al., 2010 [95]
C57Bl/6J 2.5% DSS
12 cycles of: 7 days
DSS followed by 10
days water
Seril et al., 2002 [96]
Mice 3% DSS
9c y c l e so f :7d a y sD S S
followed by 14 days
water
Okayasuet al., 2002 [97]
C57Bl/6J 4% DSS
4c y c l e so f :4d a y sD S S
followed by 12 days
water
Cooper et al. 2001 [98]
Wister Rats
(Male) 5% DSS
5–8 cycles of: 4 days
DSS followed by 10
days water
Kullmann et al., 2001 [99]
Swiss Webster
mice 5% DSS
7 days DSS followed
by 14 days water,
sacriﬁced 120 days
after the 4th cycle
Cooper et al. 2000 [100]
DSS & AOM
Mice
(ICR,Balb/c,
C57Bl/6J)
AOM (10mg/kg of
body weight) & 2%
DSS in drinking
water
Single IP AOM
injection followed by
1 week 2% DSS
Tanaka et al., 2003 [101]
Rosenberg et al., 2009 [102]
Tanaka and Yasui, 2008 [103]
DSS & DMH Mice (BALB/c)
1d o s eo fD M H
(20mg/kg of body
weight) & 3% DSS
in drinking water
Single IP DMH
injection followed by
3c y c l e so f3 %D S S
Kohno et al., 2005 [104]
Tanaka et al., 2005 [105]
DSS & Iron Mice (C57Bl/6J)
2X Fe or 2X Fe-NAC
diet & 0.7%–1%
DSS
12 or 15 cycles of DSS
(1 DSS cycle = 7d a y s
DSS followed by 10
days water)
Seril et al., 2002 [96]
Seril et al., 2002 [106]
Seril et al., 2003 [107]
Seril et al., 2006 [108]
Abbreviations: AOM, azoxymethane; DMH, 1,2-dimethylhydrazine; IP, intraperitoneal.
The untreated control APCmin/+ mice had no evidence of
invasive colorectal cancer while 40% of the DSS-treated
APCmin/+ mice developed colorectal cancer. The incidence
of adenocarcinoma in WT mice exposed to DSS was 12.5%
and the mean number of tumors per tumor-bearing mouse
was 1.0. All the DSS-treated WT mice had polypoid tumors
with no evidence of ﬂat lesions. These ﬁndings indicate
that both the mutation of APC and inﬂammation accelerate
the formation of colitis-associated dysplasia and their pro-
gression into invasive carcinoma. While inﬂammation is an
augmenting factor for colorectal cancer development, loss
of heterozygosity of the APC gene is also important in the
formation of colorectal neoplasia [100].
4.1.2. p53. The loss of p53 is one of the early mediators in
CAC [112, 113]. In the studies, DSS-colitis was induced in
p53+/+, p53+/−, and p53 KO mice in C57Bl/6 background.
The mice were treated with 3 to 4 cycles of DSS followed by
120 days of regular water treatment after the ﬁnal cycle of
DSSadministration. Eachcycleconsistedof4daysof4%DSS
followedby17daysofregularwater.Therewerenocolorectal
lesions in untreated p53+/+, p53+/− or p53 KO mice, while
colorectal cancers developed in 57% of the DSS-treated p53
KO mice, 20% of p53+/−, and 20% of p53+/+. The DSS-
treatedp53KOmicehadalargernumberoflesionsincluding
cancers and dysplasias per mouse as compared to p53+/−
or p53+/+ mice. In the p53 KO group, 38.5% of the mice
exhibited ﬂat cancers, 46.1% ﬂat dysplasias, 15.4% polypoid
cancer, and 0% polypoid dysplasias. In contrast, the DSS-
treated p53+/− mice showed more polypoid neoplasms:
ﬂat cancers were seen in only 16.7% of the mice, ﬂat
dysplasias in 0%, polypoid cancers in 5.6%, and polypoid
dysplasias in77.8%.Interestingly,all theDSS-treatedp53+/+
mice showed polypoid dysplasias. Therefore, ﬂat cancers8 Journal of Biomedicine and Biotechnology
Table 3: Examples of CAC in genetically engineered mice with DSS treatment.
Gene Treatment Cycles Invasive
carcinoma (%) References
Apc min+/−
Apc min+/−
4% DSS
2% DSS
2
1
40
100
Makiyama et al., 2005 [110]
Tanaka et al., 2006 [111]
iNOS−/−
iNOS+/+
1% DSS + high
Iron 15 68
65 Van Assche et al., 2005 [87]
P53−/−
P53+/−
P53+/+
4% DSS 3 + 120 days
53.9
22.3
0
Rutgeerts et al., 2006 [83]
Msh2−/−
Msh2+/−
Msh2+/+
5% DSS 3–8
16.7
8
13.3
Cooper et al., 2000 [100]
Brp39−/−
Brp39+/+ AOM + 3.5% DSS 3 37.5
87.5 Segawa et al., 2010 [26]
Abbreviations: AOM, azoxymethane; APC adenomatous polyposis coli; DSS, dextran sulfate sodium; NOS, nitric oxide synthase; Brp39, breast regression
protein 39.
are highly associated with p53-deﬁcient genotype while
polypoid dysplasias are associated with p53+/− and p53+/+
genotypes. In addition, nuclear translocation and mutation
of β-catenin were observed only in polypoid lesions (91%
and 43.7%, resp.). This result strongly suggests that the
loss of p53 enhanced induction of CAC, and particular ﬂat
cancer-lesions,anddysregulationofβ-cateninsignaling plays
an important role in the formation of polypoid-dysplastic
lesions in the p53 model of colitis-associated neoplasia.
Chang et al. used C57BL/6 x CBA mice and showed the sim-
ilar results. After treatment with 2 cycles of 4% DSS (7days
DSS treatment with 14 days interval), neoplastic lesions
developed in 100% of p53 KO, 46.2% of p53+/−, and 13.3%
of p53+/+ mice [114]. Invasive carcinoma was seen in 5%
of p53 KO mice. Furthermore, the majority of lesions in p53
KO were ﬂat while those seen in p53+/+ mice were polypoid
dysplasia. However, nuclear translocation of β-catenin was
observed in both ﬂat and polypoid neoplasias [115].
4.1.3. Inducible Nitric Oxide Synthesis (iNOS). iNOS acti-
vation causes prolonged production of NO at the cytotoxic
level, and iNOS is overexpressed in colonic mucosa of
UC patients and may contribute to pathogenesis of colitis
associated neoplasia [116, 117]. In one study, iNOS KO and
iNOS+/+ mice (in C57BL/6 background) were treated with
DSS (1% DSS for 15 cycles, which consisted of 7 days DSS
and 10 days interval with regular water per each cycle) and
were fed with a high-iron diet AIN76A. Both groups devel-
oped well-diﬀerentiated adenocarcinomas in the intestine at
the similar prevalence at the age of 255 days (68.4% in iNOS
KO and 65.2% in iNOS+/+ mice). The tumor multiplicity
was also similar between the two groups (2.0 ± 0.2i ni N O S
KO and 1.5 ± 0.2 in iNOS+/+ mice). These results show that
there is no diﬀerence in UC-associated cancer development
in iNOS KO and iNOS+/+ mice, suggesting that in the
absence ofiNOS,the othertwo isoforms ofNOS,endothelial
NOS (eNOS) and neuronal NOS (nNOS), may take over the
roleofiNOSandmayplayaroleinnitrosativestress andUC-
associated carcinogenesis in this model [118].
4.1.4.Msh2. Msh2is oneofthemismatch repair genesthatis
frequently mutated in hereditary nonpolyposis colon cancer
(HNPCC). It is unclear whether loss of mismatch repair
contributes to development of colitis associated neoplasia in
humans [119, 120]. In a study, colitis was induced in Msh2
KO, Msh2+/−, and Msh2+/+ mice on a 12910LA x C57BL/6
background using DSS treatment. There was no diﬀerence
in severity of chronic colitis as well as incidence of colonic
neoplasms among the diﬀerent genotypes. After 5 cycles of
DSS treatment, 12.5% of Msh2 KO, 8.0% of Msh2+/−,a n d
46.7% of Msh2+/+ mice developed high-grade dysplasia.
Similarly, colonic adenocarcinoma of the mucinous type
were seen in 13.3% of Msh2 KO, 8.0% of Msh2+/−,a n d
16.7% of Msh2+/+ mice although the majority (77.8%) of
the Msh2 KO mice tumors were microsatellite instability
high opposed to none of the Msh2+/− and Msh2+/+ mice.
However, future studies using these mice may elucidate
the role of the DNA mismatch repair in colitis-associated
neoplasia in humans [121].
4.1.5. Brp39. Brp39 is a mouse homologue of Chitinase 3-
like-1 (CHI3L1, YKL-40, HC-gp39). CHI3L1 is induced on
CECs and macrophages under inﬂammatory conditions and
plays a key role in host-microbial interactions by enhancing
the adhesion and invasion of bacteria into the CECs [122].
To examine the biological function of this molecule in the
development of CAC, our lab has developed an AOM-
pretreatedchronicDSS-inducedCACmodelusingBrp39KO
and Brp39+/+ mice. Brp39 KO mice were more susceptible
to the chronic DSS colitis with increased proinﬂammatory
cytokine production and inﬂammatory cell inﬁltration in
the colonic mucosa as compared to Brp39+/+ mice. Subse-
quently, the Brp39+/+ mice had a higher incidence of CAC
(87.5%)thanBrp39KOmice (37.5%),suggesting that Brp39
plays a key role in the development of CAC.
4.2. Iron Supplemented DSS Model. Iron-deﬁciency anemia
is a frequent complication in UC patients due to colorectal
bleeding, and these patients are clinically treated with ironJournal of Biomedicine and Biotechnology 9
supplements[123].However,Seriletal. reported thatdietary
iron supplementation enhanced the development of CAC in
a 1% DSS-induced colitis model, and the histology of the
tumors was fairly similar to that of human CAC [96]. In
the chronic DSS-treated mice, 88% of iron-enriched diet
fed mice developed colorectal tumors while only 19% of
the control developed the tumors, suggesting that dietary
iron may enhance the development of CAC in IBD patients
presumably by augmenting oxidative and nitrosative stress
[96, 108].
4.3. Carcinogen-Induced CAC Model. There are eﬀective
chemical agents, which directly or indirectly, induce
colorectal tumors in laboratory animals. Many researchers
use azoxymethane (AOM, methyl-mrthylimino-oxido-
azanium), 1,2-dimethylhydrazine (DMH), and/or methyl
azoxy methane (MAM) acetate in the animal models of
CAC. AOM is the most widely used carcinogen in the colon.
AOM- or DMH-induced colorectal cancer in rats shows
many similarities to human colorectal cancer; however,
there are some diﬀerences between the two. Although many
human colorectal cancers arise from adenomatous polyps,
AOM- or DMH-induced rat adenocarcinoma in the colon
develop in the background of ﬂat mucosa without polyp
formation [124]. In addition, it has been reported that
the incidence of metastasis is relatively low in AOM- or
DMH-induced adenocarcinoma, while colorectal cancer
patients havean approximate50% metastatic rate in regional
lymph nodes at the time of diagnosis [102]. Despite these
diﬀerences, the chemical-induced CAC models are widely
used, and have provided valuable information regarding the
pathogenesis of CAC.
AOM is the oxide of azomethane and is used in cancer
research to enhance the formation of colorectal tumors in
rodents. AOM augments the expression of cyclooxygenase
(COX)-2 (but not COX-1) in colonic tumors [125], which,
in turn, suppresses transforming growth factor-β receptor 2
(TGFBR2) expression in CECs [126] and activates intrinsic
tyrosine kinase of epidermal growth factor receptor (EGFR)
[127] in laboratory rodents. After treatment with subcuta-
neous or intraperitoneal injection of AOM (10mg/kg body
weight, in general) followed by multiple cycles of DSS, the
treated mice developed colonic tumors within a relatively
short time period [101, 102]. AOM/DSS-induced colonic
dysplasia and adenocarcinoma showed nucleic translocation
of β-catenin and positive staining for COX-2 and inducible
nitric oxidesynthesis, butnoimmunoreactivity top53[128].
AOM-treated APCmin/+ mice have also shown an enhanced
expression of COX-2 in the early phase of colitis-associated
tumors[42].Interestingly, molecularanalysisclearlydemon-
strated that AOM exposure induces the mutations in codons
33and 34,whileDSSexposure inducesmutationincodon32
of the mouse β-catenin gene [105]. A single dose of various
colon carcinogens including AOM and DMH, followed by
exposure to 2% DSS just for one week is eﬀective enough to
induce colonic tumors [104, 105], suggesting that there is no
correlation between the severity of colitis and development
ofcolonictumors.Exposuretobacteria(bytransferring from
germfree to a speciﬁc pathogen free condition) followed by
repeated AOM treatment for six times induces CAC in IL-
10 KO mice, but not in WT mice. The results support the
notionthatinﬂammation itselfplaysanimportantroleinthe
initiation and progression of CAC [129].
4.4. Carrageenan-Induced CAC. Carrageenan (CGN) are
high molecular weight (>200kDa) gelatinous polysaccha-
rides, which are extracted from red seaweeds, and are widely
used as thickening and stabilizing agents in the food or other
industry products. Although the native form of OGN is
thought to be harmless, a degraded form of CGN (so called
Poligeenan or dCGN) with acid treatment at high tempera-
ture, around 80◦C, reduces the molecular weight (<50kDa)
and may have toxic eﬀects in animal models including rats,
guinea pigs and monkeys by causing colonic ulceration and
neoplasia in the gastrointestinal tract [92]. CGN-induced
squamous metaplasia persisted in almost all experimental
rats and progressed irreversibly, and the tumors included
adenoma, adenocarcinoma, squamous cell papilloma, and
squamous cell carcinoma [91]. However, the role of both
CGN and dCGN as carcinogens still remains controversial.
Tobacman’s group demonstrated through in vitro studies
that the native form of CGN induces IL-8 production in
NCM460 human CEC line by enhancing the activation of
NF-κBp a t h w a y[ 130, 131]. Furthermore, dCGN induces
cellular aggregation and enhances ICAM expression and
TNFα production in monocytes through NF-κBa c t i v a t i o n
bothin vivo and in vitro [93]. These studies suggest that both
native and degraded CGN may have a pronounced eﬀect on
the exertion ofan inﬂammatory pressure oncolonicmucosal
cells including CECs and monocytes/macrophages.
5.Involvement of SolubleMediatorsin CAC
A complicated immune network is involved in CAC devel-
opment. To understand this mechanism in CAC, we have
summarized the main interacting cells and soluble factors
in Figure 1, and major signaling pathways involved in CAC
development in Figures 2 and 3.W eh a v ea l s os u m m a r i z e d
each major factor in CAC developmentin this section.
5.1. Proinﬂammatory Cytokines/Factors
5.1.1. TNFα. TNF produces multiple eﬀects including
altered cell proliferation and cell death through distinct
signaling cascades resulting from binding to TNFR type-I
(TNFR1) and type-II (TNFR2) [132]. In general, cell death,
altered target gene transcription, and cytokine production
are mediated by TNFR1, while engagement of TNFR2 has an
antiapoptoticeﬀect,actingthroughanNF-κBpathway[133].
These receptor-mediated signalings regulate inﬂammatory
cell inﬁltration in the lamina propria, epithelial/mucosal
damage, and cytokine expression in colonic mucosa in many
animal models of colitis and CAC [18]. In fact, TNFR1
knockout (KO) mice showed a much milder form of colitis
with a reduced incidence of CAC in response to the AOM
pretreated DSS-induced colitis as compared to WT mice
[134].10 Journal of Biomedicine and Biotechnology
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Figure 1: A complicated immune network in colitis-associated cancer (CAC). Previous and current data of CAC in animal models and
in man suggest that many cell types as well as soluble factors are involved in the pathogenesis. High levels and continuous production
of inﬂammatory mediators, including cytokines and chemokines by immune cells in lamina propria, may be strongly associated with
the pathogenesis of CAC as shown in this ﬁgure. Although colonic epithelial cells (CECs) also produce a wide variety of cytokines and
chemokines (e.g., IL-8, IL-23, TNFα,T G F β, KC, MCP-1, and MIP1a) under inﬂammatory conditions and the following CAC development,
these factors in CECs are not indicated here in order to simplify the ﬁgure. The abbreviations used in this ﬁgure are: Breg, regulatory B cells;
Ca, calcium, CCL2, chemokine (C-C motif) ligand 2; CCR2, chemokine (C-C motif) receptor 2; COX-2, cyclooxygenase-2; DC, dendritic
cells; EGFR, endothelial growth factor receptor; IGFR, insulin-likegrowth factor receptor; IL, interleukin; MCP, monocyte-chemoattractant
protein; Mφ, macrophages; NSAIDs, nonsteroidal anti-inﬂammatory drugs; TGF, transforming growth factor; Th, T helper; TNFR, tumor
necrosis factor receptor; Treg, regulatory T cells; CHI3L1, chitinase 3-like-1.
TNF initiates and perpetuates many inﬂammatory reac-
tions and eﬃciently recruits activated inﬂammatory cells to
the site of injury or inﬂammation [135]. TNF also eﬃciently
activates NF-κB, MAPK and cell-death signaling pathways.
Dysregulated TNF production has been identiﬁed in a var-
ious inﬂammatory disorders including rheumatoid arthri-
tis, IBD, psoriasis, ankylosing spondylitis, and refractory
asthma. TNF-blocking agents have been widely utilized for
treatment of said disorders. In particular, these agents show
as i g n i ﬁ c a n te ﬃcacy in refractory IBD compared to other
anti-inﬂammatory and/or immunosuppressive medications
[136]. Etanercept, a recombinant fusion protein consisting
of the extracellular ligand-binding region of recombinant
human TNFR attached to the constant (Fc)region of human
IgG1, binds to circulating TNF, inhibits its attachment to
TNFRs, and eﬃciently blocks the TNF-mediated inﬂam-
matory pathway in rheumatoid arthritis [137]. However,
while it eﬃciently blocks the tumor formation in AOM-
induced CAC model, the eﬃcacy of Etanercept in IBD is
quitelimited ascomparedtomonoclonalantibodies directed
against TNFα (e.g., Inﬂiximab) [138]. In contrast, anti-TNF
antibodies show unclear eﬃcacy (anti- or procarcinogenic
eﬀects) in colorectal cancer development [139, 140].
5.1.2. IL-6. IL-6 (also known as IFN-β or B-cell stimulator
factor-2) plays an important role in the transition from
acute inﬂammation to chronic colitis, as well as innate
immunity to acquired immunity [141]. IL-6 is mainly
produced by macrophages after being exposed to speciﬁc
microbial molecules, so called pathogen associated molec-
ular pattern (PAMPs). IL-6 binds to a cell-surface receptor
complex,which consistsofan IL-6Rαchain (CD126)and the
signal-transducing component gp130 (CD130). The ligand-
receptor interactions initiate signal transduction cascades
through transcription factors, Janus kinases (JAKs) and
Signal Transducers and Activators of Transcription (STATs)
[142]. In addition, IL-6 enhances the diﬀerentiation ofJournal of Biomedicine and Biotechnology 11
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Figure 2: The JAK/STAT3 signaling pathway transmits information from cytokine/chemical signals outside the cell, through the cell
membrane, and into the gene promoters on the DNA in the cell nucleus, which causes DNA transcription and activity in the cell. After JAK
is activated by autophosphorylation, STAT3 protein then binds to the phosphorylated receptor. STAT3 is phosphorylated and translocated
into the cell nucleus, where it binds to DNA and promotes transcription of genes responsive to STAT. TGF-β controls proliferation, cellular
diﬀerentiation, and it acts as an antiproliferative factor in normal epithelial cells, and at early stages of oncogenesis. In the SMAD pathway,
the TGF-β dimers bind to a type-2 receptor which recruits and phosphorylates a type-1 receptor. The type-1 receptor then recruits and
phosphorylates a SMAD. This SMAD then binds to the common SMAD and forms a heterodimeric complex. This complex then enters the
cell nucleus where it acts as a transcription factor for the various genes, including those to activate the MAP Kinase pathway, which triggers
apoptosis. The TAK1-NLK-STAT3 pathway cascade participates in TGF-β-mediated mesoderm induction. Finally, MyD88 is a universal
adaptor protein that is used by most of TLRs to activate the transcription factor NF-κB. These signals are closely associated with colitis-
associated cancer formation. The abbreviations used in this ﬁgure are: Erk, extracellular signal-regulated kinases (=MAPK); HAD, histone
deacetylase; IKK, IκB inhibitor; IRAK, IL-1 receptor associated kinase; JAK, Janus kinase; NLK, nemo-like kinase; MAPK, microtubule-
associated protein kinase; MEK, mitogen activated protein kinase; mTOR, mammaliantarget of rapamycin; MyD88, myeloid diﬀerentiation
primary response gene 88; PI3K, phosphoinositide 3-kinase; STAT, signal transducer and activatoro ft r a n s c r i p t i o n ;T A K ,T G F - β activated
kinase; TBR, TGF-β receptor; TCF, T cell factor; TGF, transforminggrowth factor; TLR, Toll-like receptor.
Th17 cells under a combination with immunosuppressive
cytokines (e.g., TGFβ)[ 143, 144]. IL-6 expression is signif-
icantly increased in IBD and in murine models of colitis,
and the blocking of IL-6 signaling signiﬁcantly inhibits
the severity of colitis in murine models [145–150]. A
randomizedpilotstudyofhumanized anti-IL6R inactiveCD
patients showed no beneﬁcial eﬀect in improvement with
endoscopic and histologic examination, although an 80%
improvement of clinical symptoms in patients who were
treated with the Ab as compared to 31% improvement in
placebo patients was noted [151].
IL-6 production is highly upregulated in colorectal-
tumor developing APCmin mice and animal models of CAC
[152, 153]. In human, increased serum levelsof IL-6 produc-
tion have been identiﬁed in colorectal cancer patients [154].
IL-6 expression is mainly regulated by NF-κBa c t i v a t i o n ,
and IL-6 acts on both CECs and immune cells [155, 156].
Eﬀects of IL-6 are mediated mainly by transcription factor
STAT3 activation in cancer cells, and STAT3-mediated cell
activation further promotes cell-survival and cell-cycle pro-
gression of premalignant as well as cancer cells by inducing
expression of antiapoptotic genes (e.g., Bcl2, Bcl-xL) and
proliferation-associated genes (e.g., c-Myc, Cyclin D1) [157,
158]. Interestingly, inhibition of IL-6 signaling signiﬁcantly
reduced tumor development in AOM-induced CAC model,
suggesting IL-6 trans-signaling plays a pivotal role in the
development of colon cancer [159]. Li et al. recently demon-
strated that expression of suppressor cytokine signaling 3
(SOCS3), which is the major negative regulator of STAT3,
was signiﬁcantly reduced in patients with UC-accompanied
with colon cancer as compared to inactive UC or active UC,
who had no colon cancer progression [160]. Therefore, IL-6
trans-signaling andSTAT3activation mustbea potentialand
attractive therapeutic target for CAC progression.
5.1.3. IL-23/Il-12/IL-17. IL-23 is a heterodimeric cytokine
consisting of two subunits, p40 (which is shared with IL-
12) and p19 (also called as IL-23α subunit). IL-23 binds to
a speciﬁc receptor, which isformed by IL-12RB1and IL-23R.
Both IL23 (p19/p40) and IL-12 (p35/p40) can activate the
STAT4 transcription factor, and subsequently stimulate the
production of IFNγ. In addition, IL-23, TGFβ and IL-6 con-
jugationallystimulatena¨ ıveCD4+Tcellstodiﬀerentiateinto
Th17 cells, which produce the proinﬂammatory cytokine IL-
17 [161]. IL-23 plays an important role in the inﬂammatory
response against infection, and the expression is increased
in IBD [162, 163] and in colon cancer [164]. Shan et al.
showed antitumor activity of IL-23 in a murine model of
cancer, in which murine colon carcinoma cells retrovirally12 Journal of Biomedicine and Biotechnology
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receptor Frizzled, which transactivates EGFR signalingby MMP-mediated release ofsoluble EGFR ligands.Activated EGFR transactivates β-
catenin via receptor tyrosine kinase-PI3K/Aktpathway,and β-catenin also formsheterodimer with EGFR and further activate EGF pathway.
Direct activationofEGFR utilizingEGF-familyligandsinducesCHI3L1expression,whichbinds toaputativereceptor oncell membraneand
leadstoPI3K-mediatedphosphorylationofAktfollowedby β-catenintransactivation.Asshowninthisﬁgure, WntandEGFR pathwayshave
been reported to closely interact in tumorigenesis by crosstalking and coactivating tumor progression. The activation of ASK1, following
of TNF/TNFR1 and/or IL-1/IL-1R ligation, activates SAPK/JNK and MAPKp38 followed by increased production of MMPs and cytokines.
NF-κB signal is also activated by TNF and IL-1, which is highly involved in the development of chronic colitis as well as colitis-associated
cancer formation. The abbreviations used in this ﬁgure are: ASK-1, apoptosis signal-regulating kinase 1; ATF-2, activating transcription
factor 2; BAD, Bcl2-antagonist of cell death; Bcl2, B-cell lymphoma 2; CHI3L1, chitinase 3-like-1; EGF, epidermal growth factor; Elk-1, Ets
like gene 1; GSK3β, glycogen synthesis kinasse 3 beta, Lef-1/TCF, lymphoid enhancer-binding factor-1/Tcell factor; IKK, IκBk i n a s e ;I R A K ,
IL-1 receptor associated factor; LPR5/6, lipoprotein-related receptor 5 and 6; PI3K, phosphoinositide 3-kinase; SAPK/JNK, stress-activated
protein kinase/c-Jun NH2-terminal kinase; TBP, TATA-binding protein; TNFR1; Tumor necrosis factor receptor 1; TRADD, TNF receptor
1-associated death domain;TRAF, TNF receptor associated factor.
transduced with mouse IL-23 gene were subcutaneously
injected [165]. Interestingly, IL-23 secreted by tumor cells
eﬃciently suppressed the growth of tumor and the survival
of mice by enhancing the production of IFNγ, IL-12, and
TNFα [165]. IL-23 and Th17 cytokines act coordinately to
maintain thebalance between toleranceand immunity in the
gastrointestinal tract [166].
5.1.4. Cyclooxygenase (COX). COX is an important enzyme,
which is responsible for forming prostanoids including
prostaglandins. COX can convert arachidonic acid to
prostaglandin H2, the precursor for prostaglandins, which
act on a variety of cells and cause multiple actions including,
but not limited to, muscular constriction and mediation
of inﬂammation. So far, there are three COX isozymes:
COX-1, COX-2, and COX-3 (a splice variant of COX-1).
COX-1 is found in most mammalian cells constitutively,
while COX-2 is undetectable in most normal cells but
becomes abundant in macrophages and other cells under
inﬂammatory conditions.
It has been reported that COX-2 is upregulated in
various malignant cells and has a key role in inﬂammation-
associated carcinogenesis. Oshima et al. ﬁrst demonstrated
the role of COX-2 in colorectal tumorigenesis in mice
carrying a mutant Apc gene encoding a product truncated
at a 716 (Apc Δ716), a mouse model of human familial
adenomatous polyposis [167]. Another report also has
suggested that intestinal epithelial cells upregulated Cox-2
expression in a TLR-4 and MyD88-dependent fashion.
This signaling is required for optimal proliferation and
protection against apoptosis in the injured intestine, while
TLR4 may lower the threshold for carcinogenesis in an
AOM/DSS-induced cancer model [168]. In the same model,
endogenous administration of PGE2 treatment increased
mucosal expression of COX-2, thus PGE2 involves in the
TLR-4-mediated intestinal tumorigenesis [169].
COX inhibitors are compounds that can eﬃciently block
the action of COXenzymes. Nonsteroidalanti-inﬂammatory
drugs (NSAIDs) are widely utilized inhibitors for both
of COX-1 and COX-2 enzymes. NSAIDs that selectively
block the COX-2 enzyme but not COX-1 are called COX-
2 inhibitors that have less adverse eﬀects. Selective COX-
2 inhibitors signiﬁcantly reduced the number and size of
intestinal polyps in Apc Δ716 mice [167, 170]a n dt h eJournal of Biomedicine and Biotechnology 13
occurrence of neoplasia in p53-deﬁcient mice treated with
DSS [171]. Celecoxib, another COX-2 inhibitor, prevents a
wide variety of cancers including animal models of urinary
bladder cancers [172], human breast cancer cells [173],
human colon cancer cells [174], and human lung cancer
[175], while clinical trials participants taking celecoxib had a
signiﬁcant increase in their blood pressure, which may have
aﬀected their heart disease risk [176, 177].
Besides the NSAIDs, salicylates, such as aspirin (acetyl-
salicylic acid), methyl salicylate and sodium salicylate, are
widely used as drugs for their analgesic, anti-inﬂammatory,
and antipyretic eﬀects. Salicylates, including aspirin, inhibit
prostaglandin synthesis, and aspirin is able to irreversibly
inactivatebothCOX-1andCOX-2.Morerecently,ithasbeen
reported that regular intake of aspirin has been associated
with a decreased incidence of colon cancer [178]. Some
double-blind randomized placebo-controlled clinical trials
indicate that daily consumption of aspirin (75–80mg) can
lead to a 40%–50% decrease in the risk of developing
colon cancer [179, 180]. The aspirin-mediated antitumor
eﬀect is also supported by animal models, including 1,2-
dimethylhydrazine-induced colon cancer model in Sprague-
Dawley rats [181], AOM-induced colon carcinogenesis in
F344 rats [182], and intestinal adenomas model in APCmin/+
mice [183]. In addition, antineoplastic eﬀect can be achieved
by eating salicylic acid-rich foods (e.g., a wide range of fruit,
vegetables, herbs, and spices) at concentrations as low as
100nM/mL [184].
5.2. Regulatory Factors
5.2.1. IL-10. IL-10 (also known as human cytokine synthesis
inhibitory factor: CSIF) is a key anti-inﬂammatory cytokine
produced primarily by monocytes, T cells and B cells. IL-
10 can block NF-κB activity, and also regulates the JAK-
Stat signaling pathway [185]. IL-10 interacts with IL-10
receptor α subunit (IL-10RA) and inhibits the synthesis of
proinﬂammatory cytokines such as IL-6 [18, 186]. IL-10
KO mice develop spontaneous colitis, which is similar
t oh u m a nI B D ,i np a r t i c u l a rC D[ 187]. These mice also
develop colitis-associated cancer, which is associated with
the overproduction of Th1 cytokine [61]. AOM and DSS
treatment promotes inﬂammation-mediated colonic tumor
g r o w t hi nI L - 1 0K Om i c e[ 67]. Furthermore, Helicobacter
hepaticus infection promotes AOM-induced tumorigenesis
as comparedtoAOMtreatment alonein IL-10KOmice[68].
We have summarized chronic colitis and CAC development
i nI L - 1 0K Oi nS e c t i o n s2 and 3 in this review.
5.2.2. Transforming Growth Factor (TGF)-β. TGF-β has an
antiproliferative eﬀect in normal epithelial cells as well as
early stage of oncogenesis [188]. TGFβ has three protein
precursors,theso-calledTGF-β1,-β2,and-β3,andeachhave
an N-terminal short (20–30 amino acids) signal peptide.
The C-terminal region becomes the mature TGF-β protein,
which makes a homodimer to produce an active molecule
[189]. There are three TGF-β receptors: types I and II have a
high aﬃnity for TGF-β1, and type III has a high aﬃnity for
both TGF-β1, and -β2. In most of cases, an activated TGF-β
ligand will initiate the TGF-β signaling by binding these
receptors. TGF-β can induce FoxP3 in human CD4+ CD25+
T cells and regulate the development of CD25+ regulatory T
cells [190]. In normal cells, TGF-β blocks cell cycles at the
G1 stage and stops proliferation and diﬀerentiation of cells
and promotes apoptosis [191]. However, once an epithelial
cell has been transformed into an adenocarcinoma, parts
of TGF-β signaling are mutated, and subsequently TGF-β
promotestumorgrowth, migration, invasion, and metastasis
at an advanced stage of CAC [192]. Recently, Becker’s group
elegantly demonstrated that TGF-β receptor II-deﬁcient
mice developedan increased number of tumors as compared
to WT mice. In contrast, TGF-β transgenic mice showed
signiﬁcantly less number of tumors as compared to WT. The
authorsconcludedthat TGF-β signaling in inﬁltrating T cells
suppresses coloncancerprogression byinhibiting IL-6trans-
signaling in tumor cells [159]. Overall, TGF-β seems to have
ap r o t e c t i v ee ﬀect on chronic colitis and CAC development,
at least in early stages [193].
Insulin-Like Growth Factor (IGF). IGFs are polypeptides,
which show a high sequential homology to insulin. IGFs
generate a complex system with two ligands (IGF-1 and
IGF-2), two receptors (IGF1R and IGF2R), a family of six
IGF-binding proteins (IGFBP 1–6), and associated IGFBP
degrading enzymes [194, 195]. IGF1R activation leads to
autophosphorylation of receptor and activation of signaling
cascades includingthe GRB2/Ras/ERKand IRS-1/PI3K/AKT
pathways [196]. Of note, IGF-2 is overexpressed in many
solid tumors including colon cancer [197], and also loss of
imprinting (LOI), an epigenetic alteration, of IGF-2 gene
(IGF2) was discovered in many types of cancer including
ovarian, lung, liver, and colon [198]. Approximately 10%
of the population shows LOI of IGF2, and it seems to
be associated with a personal and/or familial history of
colorectal neoplasia since the variant showed a 5-fold
increased frequency of colon cancer [199, 200]. Kaneda et
al. reported that LOI and APCmin double heterozygous mice
have an enhanced sensitivity to IGF-2 signaling, and AOM-
treatment in those mice showed a 60% increased number
of premalignant aberrant crypt foci formation as compared
to LOI(−)l i t t e r m a t e s[ 201]. These results strongly suggest
that epigenetic alterations in IGF2 in normal cells may aﬀect
cancer risk by altering the balance of diﬀerentiated and
undiﬀerentiated cells [201].
As described above, IGFs and IGFRs have been highly
implicated in cancer pathophysiology. It has been reported
by some groups that IGF1R inhibition by administrating
an antagonistic monoclonal antibody against IGF1R (des-
ignated EM164) [202] or selective kinase inhibitor [203]
(designated NVP-ADW742) showed antiproliferative and/or
proapoptotic eﬀects in solid tumors, suggesting that selective
IGF1R inhibitors should be one of the useful therapeutic
strategies in treating cancers.
Endothelial Growth Factor (EGF). EGF is a low molecular
weight (6KDa) polypeptide, which plays a pivotal role in14 Journal of Biomedicine and Biotechnology
cellular proliferation, diﬀerentiation, cell growth, and cell
survival by binding with high aﬃnity to its receptor EGFR
on the cell surface and subsequently stimulates the intrinsic
protein-tyrosine activity of EGFR [204–206]. On the basis
of several clinical trials, EGF appears promising for the
treatment of IBD. An approximate 80% remission rate has
been demonstrated in left sided UC patients with daily EGF
enemas for 2 weeks as compared to 8% in placebo group
(P<. 001) [207]. Rabamipide, an amino acid analogue of
2-(1H)-quinolinone, eﬃciently upregulates EGF and EGFR
expression. A signiﬁcant improvement was observed in the
clinicaland endoscopicﬁndings with twicedailyRabamipide
enemas, which were given to patients with UC proctitis for
one month [110]. There is a big concern, however, that
systemic use of EGF might have potent mitogenic eﬀect by
increasing tumor development and/or progression in APC
Min mice [208]. EGFR signaling seems to be required for
early stages of colonic carcinogenesis by upregulating cyclin
D1 and Cox-2 expressions in microadenomas in AOM-
induced cancer model [209]. EGF can form a complex
with β-catenin, possibly through receptor tyrosine kinase-
PI3K/Akt pathway, and further activate Wnt signaling
pathway [210]. As shown in Figure 3, cross-communication
between Wnt- and EGFR-signaling pathways allows the
integration of the diversity of stimuli in CECs and promotes
tumor progression [210]. Furthermore, EGFR signaling
augments the expression of epithelial CHI3L1 [211], which
further promotes tumor angiogenesis and migration [212].
EGF signaling also upregulates the proliferation of aberrant
crypt foci, which is the precursor to colon cancer [213].
In summary, EGF may be a useful therapeutic reagent for
treating severe UC, but at the same time, it has a subsequent
risk of malignant change in the early stage of colon cancer.
5.2.3. Calcium. Calcium is an essential dietary mineral,
which is commonly included in milk products and dark
greenvegetables.Ithasbeenreportedthatacalciumenriched
diet signiﬁcantly reduces the number of total aberrant crypt
foci in AOM-treated mice or rats [214]. Other reports
utilizing animal models also support ﬁndings of calcium’s
ability to inhibit colorectal cancer development [215, 216].
According to a report of the American Cancer Society’s Can-
cer Prevention Study II Nutrition Cohort, which recruited
more than 120,000 examinees, men and women who had
the highest intakes (approximately 1200mg per day) of
calcium showed a modestly reduced risk of colorectal cancer
compared with those who had the lowest intakes of calcium
[217]. Many other studies also report that individuals who
had a modest to high calcium intake reduced their risk of
cancer[218–220].Theexactmechanistic ofactionofcalcium
is still unclear, but it binds to bile acids and fatty acids in the
gastrointestinal tract to form insoluble complexes (calcium
soaps). In addition, calcium may suppress cell proliferation
in the lining of the colon or cause proliferating colon cells to
undergo diﬀerentiation [221].
5.3. Chemokines. Chemokines are small chemotactic
cytokines, and classiﬁed as 4 diﬀerent types: CC-, CXC-, C-,
and CX3C-chemokines. Chemokines bind to chemokine
receptors, which are G protein-coupled receptors, and
they are divided into four families: CXCR (bind CXC
chemokines), CCR (bind CC chemokines), CX3CR1 (binds
to CX3C),and XCR1(binds to XC chemokines) [222]. Some
chemokines have proinﬂammatory eﬀects and eﬃciently
promote migration of hematopoietic and nonhematopoietic
cells to the site of infection or inﬂammation. In contrast,
otherchemokines keeptissuehomeostasis duringthenormal
process of tissue development. TNFα induces expression
of several chemokines in colonic mucosal cells during the
development of IBD [223]. TIR8 (also called as SIGIRR, a
member of IL-1/TLR family) deﬁcient mice cause severe
colitis with cancer formation after AOM/DSS-induced
colitis, and these mice showed signiﬁcantly increased
production of KC/CXC, MCP-1/CCL2, and MIP1α/CCL3
chemokines by tumor cells [224]. These chemokines
enhance leukocyte inﬁltration and tumor growth/migration.
In particular, CXC and MCP-1 chemokines are known
for their eﬀects in enhancing angiogenesis in colon cancer
[225,226].Popivanovaetal.also reportedthatMCP-1/CCL2
is a crucial mediator of colon cancer development since
CCR2 (a speciﬁc receptor for MCP-1/CCL2) KO mice
showed a milder form of colitis with less macrophage
inﬁltration and a lower incidence of tumors with attenuated
COX-2 expression in the AOM challenged model [134].
In contrast, MCP-1/CCL2-antagonist-treated mice showed
reduced tumor incidence and size in the same animal model.
These results strongly suggest that MCP-1/CCL2 may be
a potential target in the treatment of colorectal carcinoma
associated with chronic inﬂammation. Furthermore,
D6 (a promiscuous decoy and receptor that scavenges
inﬂammatory CC chemokines) plays a nonredundant role
in suppressing inﬂammatory immune responses in various
organs including lungs and skin [227]. D6 KO mice were
more susceptible to chemically induced colitis, as compared
to WT mice, and failed to recover from the colitis. They
also exhibited a higher level of proinﬂammatory cytokine
productionsand increased number oftumordevelopmentin
the distal part of colon [227]. In summary, CC-chemokines
and their receptors are novel players in tumor promotion
and progression during the course of chronic colitis.
5.4. Mammalian Chitinases. Chitin, a polymer of β-1,4-N-
acetyl-glucosamine, is produced by various living organ-
isms including insects, fungi, crustaceans, and many other
organisms except mammals [228]. Chitin can be degraded
by chitinases (EC 3.2.1.14) that belong to members of
the glycohydrolase family 18, in which bacterial as well as
plant chitinases are included [229]. Chitinases have been
generally considered to lack in mammalian bodies due
to the absence of chitin. However, recent studies have
identiﬁed many chitinases including CHI3L1 [230], acidic
mammalian chitinase [231], chitotriosidase [232], and Ym-1
[233] in mammals, and the expression of these chitinases
is highly upregulated during the development of chronic
inﬂammation conditions [25].
Serum levels of CHI3L1 are signiﬁcantly elevated in
patients with IBD [234] as well as those with colorectalJournal of Biomedicine and Biotechnology 15
cancer [235], and the expression is positively associated with
bad prognosis of these patients [236, 237]. CHI3L1 plays an
important role in protecting cancer cells from undergoing
apoptosis and also eﬀects cellular invasion by strongly
binding with heparin, collagens, and hyaluronic acid, all
of these are important constituents of extracellular matrix
[238,239].Recently,ithas been reported thatnormal human
bronchial epithelial cells express CHI3L1 under mechanical
stress, which is driven by an EGFR and extracellular signal-
regulated kinases (ERK)-1/2 signaling pathways. This result
strongly suggests that direct activation of EGFR with ERK
family ligands such as EGF and heparin-binding (HB)
EGF induces CHI3L1 expression in epithelial cells [240].
Therefore, growth-stimulating eﬀects of epithelial CHI3L1
in response to inﬂammatory or stressful stimuli seems to
be a critical and physiological function in remodeling and
maintaining the basic architecture of epithelium; however,
overproduction of CHI3L1 from the epithelium must be a
cue for further prolonged inﬂammation and for develop-
ing inﬂammation-associated carcinogenesis, ironically. Cur-
rently, exact biological function of CHI3L1 as well as other
chitinases in CAC is still largely unknown. Further studies
will help clarify the critical role of mammalian chitinases in
chronicinﬂammation andthefollowingcarcinogenicchange
in epithelial cells, which will provide a rationale for the
development of novel and new type of immunotherapy for
improving the lives of patients with inﬂammation-associated
carcinogenesis.
6.Conclusions
Ithasbeenstronglyanticipatedtoimprovetheclinicalcourse
ofIBDpatientsnotonlyby creatingnew diagnosticand ther-
apeutic approaches but also by preventing inﬂammation-
associated cancer formation. Currently, a variety of genet-
ically engineered or chemically induced animal models of
CAC are available and are very useful for further analysis of
the exact mechanisms underlying the pathogenesis of CAC.
Through the animal models, we have learned that a limited
numberofinﬂammatory cytokines,chemokines,and growth
factorsplaycrucialrolesinCACdevelopment.Thus,eﬀective
and targeted anti-inﬂammatory therapies without adverse
eﬀects are warranted in order to prevent the development of
CAC in IBD patients, and the animal models would help us
with the invention of anti-inﬂammatory therapies by testing
therapeutic strategies and reagents in preclinical settings.
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